20Aug 2023
Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in NSCLC through inhibition of HIF‐1α

Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in NSCLC through inhibition of HIF‐1α

The diabetes drug canagliflozin shows promise in improving non-small cell lung cancer (NSCLC) treatment. The study reveals that canagliflozin inhibits NSCLC cell growth and enhances the effectiveness of radiotherapy. It achieves this by suppressing genes related to hypoxia-inducible factor (HIF)-1α stability, activating AMPK, and inhibiting mTOR. Canagliflozin's impact is partly through HIF-1α suppression. It also targets histone deacetylase 2 (HDAC2), which influences NSCLC prognosis. Additionally, evidence suggests that canagliflozin enhances NSCLC response to chemotherapy. This study suggests that canagliflozin could be a promising addition to NSCLC treatment when combined with cytotoxic therapy, offering hope for better outcomes.

  • #oncology

Like

Save

Share